NASDAQ · Drug Manufacturers - General

MIRA Pharmaceuticals, Inc. (MIRA) Stock

$0.75 +6.05% NASDAQ: MIRA Healthcare

Valuation

MetricValue
Price$0.75
Market Cap$31.33M
P/E Ratio-0.53
P/B Ratio3.76
P/S Ratio0.00
EPS (TTM)$-1.35
52-Week High$2.45
52-Week Low$0.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-106.96%
ROA-115.56%
ROCE-115.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-7.0M$-9.0M$-8.0M$-10.0M
Net Profit$-2.0M$-7.0M$-12.0M$-8.0M$-10.0M
EPS$-0.15$-0.48$-0.65$-0.51$-1.35
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0M$1.0M$5.0M$3.0M$11.0M
Total Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M
Cash$3.0M$0$5.0M$3.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies MT Newswires · Jul 10, 2026 MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain ACCESS Newswire · Jul 10, 2026 Clockwork.ai Launches Mira: The AI Giving 3,000+ Businesses a CFO They Could Never Afford PR Newswire · Jul 8, 2026 Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies MT Newswires · Jul 6, 2026 MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction ACCESS Newswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-6.0M$-5.0M$-6.0M$-5.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$3.0M$-2.0M$4.0M$-2.0M$4.0M
Free Cash Flow$-1.0M$-6.0M$-5.0M$-6.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.87
FCF Yield-15.12%
Quick Ratio200.08
Interest Coverage0.00
Return 1Y-42.77%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTXAN2 Therapeutics, Inc. $4.40 -5.98% -5.24 $158.47M 0.00%
APUSApimeds Pharmaceuticals US, Inc. $5.02 -8.89% -0.09 $7.58M 0.00%
IGCIGC Pharma, Inc. $0.28 -1.75% -3.34 $28.02M 0.00%
MLSSMilestone Scientific, Inc. $0.35 -2.78% -7.97 $30.96M 0.00%
MODDModular Medical, Inc. $2.72 +2.26% -0.20 $22.17M 0.00%

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. is led by CEO Erez Aminov, employs 2 people, headquartered in US, publicly traded since 2023.

MIRA Pharmaceuticals, Inc. (MIRA) stock trades at $0.75 with a market capitalization of $31.33M. The stock is valued at a price-to-earnings (P/E) ratio of -0.53, price-to-book of 3.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.60 and $2.45, and currently trades 69.4% below its 52-week high.

On profitability, MIRA Pharmaceuticals, Inc. generates a return on equity (ROE) of -106.96%, return on capital employed of -115.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides